Efficacy of omalizumab in the management of moderate-to-severe asthma in paediatric patients: a clinical evaluation

Background: Children diagnosed to have mild-to-intense allergic asthma (AA) often present with comorbid chronic sinusitis (CS), which complicates the management of their condition and adversely affects their quality of life (QoL). Omalizumab (OM), a monoclonal antibody (MCA) targeting IgE, has demonstrated potential in the management of both conditions; however, the availability of real-world data in pediatric populations is still restricted. Methods: This study involved children having mild-to-intense AA and chronic rhinosinusitis, recruited from the Pediatric Allergy and Pulmonology Clinic at Indira Gandhi Institute of Child Health, Bengaluru, India. Omalizumab was administered from January 2021 to May 2023, subcutaneously every 2-4 weeks at doses of 150-600 mg based on body mass index and baseline IgE levels. Asthma control was gauged using the Childhood Asthma Control Test (C-ACT), Asthma Control Test (ACT), fractional exhaled nitric oxide (FeNO), and lung function (LF) indices. Results: Omalizumab treatment significantly improved asthma control, shown by increased C-ACT/ACT scores (p